Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06157892 · ClinicalTrials.gov registry record · Phase 2

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

A Phase 2 study of Metastatic Breast Cancer and Breast Neoplasms, sponsored by Seagen, a wholly owned subsidiary of Pfizer.

Recruiting
Registry status
Phase 2
Development phase
172
Enrollment target
20
Study locations

NCT06157892: Recruiting Phase 2 study of Metastatic Breast Cancer and Breast Neoplasms, sponsored by Seagen, a wholly owned subsidiary of Pfizer.

NCT06157892 is a Phase 2 study of Metastatic Breast Cancer and Breast Neoplasms that is actively recruiting participants, run by Seagen, a wholly owned subsidiary of Pfizer. The registered enrollment target is 172 participants, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (16% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06157892, a Phase 2 study of Metastatic Breast Cancer and Breast Neoplasms, is actively recruiting participants, sponsored by Seagen, a wholly owned subsidiary of Pfizer.

RECRUITING
Registry status
Phase 2
Development phase
172 participants
Enrollment target
20
Study locations

Study Summary

This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer. Participants in this study must have breast cancer or gastric cancer. Participants must have tumors that have HER2 on them. This allows the cancer to grow more quickly or spread faster. There are few treatment options for patients with advanced or metastatic solid tumors that express HER2. This clinical trial uses an experimental drug called disitamab vedotin (DV). Disitamab vedotin is a type of antibody drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. This clinical trial uses a drug called tucatinib, which has been approved to treat cancer in the United States and some other countries. This drug is sold under the brand name TUKYSA®. This study will test how safe and how well DV with tucatinib works for participants with solid tumors. This study will also test what side effects happen when participants take these drugs. A side effect is anything a drug does to the body besides treating the disease.

Conditions Studied

Metastatic Breast Cancer Breast Neoplasms Gastroesophageal Junction Adenocarcinoma Advanced Breast Cancer Triple Negative Breast Neoplasms Stomach Neoplasms Metastatic Gastric Cancer Advanced Gastric Cancer HER2 Low Breast Neoplasms HER2 Positive Breast Neoplasms

Interventions

  • DRUG disitamab vedotin
  • DRUG tucatinib

Study Locations (20)

Arizona

  • Banner-University Medical Center Tucson Campus - Tucson
  • Banner-University Medical Center Tucson Campus - Tucson
  • The University of Arizona Cancer Center-North Campus Pharmacy, Attn: Kelly Myrdal - Tucson
  • University of Arizona Cancer Center - North Campus - Tucson
  • The University of Arizona Cancer Center-Main - Tucson

California

  • UC Irvine Health - Chao Family Comprehensive Cancer Center - Orange
  • UC Irvine Medical Center - Orange
  • University of California, San Francisco | HDFCCC - Hematopoietic Malignancies - San Francisco
  • UCLA Department of Medicine - Hematology & Oncology - Santa Monica
  • UCLA Hematology/Oncology - Parkside - Santa Monica

Florida

  • Moffitt Cancer Center - International Plaza - Tampa
  • H. Lee Moffitt Cancer Center and Research Institute - Tampa
  • Moffitt Cancer Center - McKinley Campus - Tampa
  • Moffitt McKinley Hospital - Tampa

Colorado

  • Colorado West Healthcare System, dba Community Hospital - Grand Junction
  • Colorado West Healthcare, dba Grand Valley Oncology - Grand Junction

Connecticut

  • Danbury Hospital - Danbury
  • The Whittingham Cancer Center / Norwalk Hospital - Norwalk

District of Columbia

  • Georgetown University Medical Center - Washington D.C.
  • MedStar Georgetown University Hospital - Washington D.C.

Trial Details

FieldValue
Enrollment Target 172 participants
Start Date 2024-05-20
Est. Completion 2029-07-28
Phase Phase 2
Seagen, a wholly owned subsidiary of Pfizer

28 total trials

What NCT06157892 shows while recruiting

NCT06157892 is an interventional study that assigns participants to a tested intervention. The registered 172 participants enrollment target is mid-sized for trials with a published cap, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (16% lower).

The record links to 10 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which disitamab vedotin is the first listed.

NCT06157892 names 20 study sites across 6 states, led by Arizona, California, Florida.

Frequently Asked Questions

What is clinical trial NCT06157892 about?

NCT06157892 is a clinical study titled "A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors". This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer...

What is the current status of trial NCT06157892?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2024-05-20. Estimated completion is 2029-07-28.

What conditions does trial NCT06157892 study?

This clinical trial studies the following conditions: Metastatic Breast Cancer, Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, Advanced Breast Cancer, Triple Negative Breast Neoplasms.

What interventions are being tested in trial NCT06157892?

The interventions under investigation include: disitamab vedotin (DRUG), tucatinib (DRUG).

Who is sponsoring clinical trial NCT06157892?

This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 28 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06157892 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06157892's enrollment target sits among peer trials

172 39th of 139 higher than 101 of 139 other Metastatic Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04801797 · 172 participants · Phase 2

    Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

  • NCT04867317 · 172 participants · Phase 3

    Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)

  • NCT05357040 · 172 participants · Phase 2

    Antidepressant Effects of Nitrous Oxide

  • NCT05587517 · 172 participants · Phase 2

    A Clinical Trial of Interventions to Support Family Surrogates of Critically Ill Patients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06157892

Source: ClinicalTrials.gov NCT06157892, the US trial registry maintained by the National Library of Medicine. NCT06157892 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.